

Vaccination to Combat as an Approach to Reduce the Antibacterial Resistance..!

Mini Review

The discovery of antibiotics is considered a significant event in the medical history saving millions of lives. The application of antibiotics extends from antibacterial activity to immuno suppressive agents, cardiovascular disease as well as anticancer [1]. It is also used widely in agricultural and animal husbandry. More than 100,000 tons of antibiotics are produced globally per year [2]. For decades efforts have been taken to control the wide over-usage of antibiotics such as through regulatory control on the availability of Over the Counter (OTC) antibiotics. However, such measure are still infective and antibiotic are available without prescription online and through self medication [3,4]. In addition, there are reports that certain pharmaceutical companies from industrialized nation distributes the drugs which are no longer approved by their home nation [5]. The increased use of antibiotics can also be attributed to the greed for revenue by pharmaceuticals sales. In developing countries, the revenue generated on drugs sale are often shared between the seller and the doctor [6]. The wide usage of antibiotics increases the selective pressure for the multi-drug resistant bacteria [5,7,8]. *B-lactamases* are enzymes which renders resistant to β -lactam antibiotic to the bacteria expressing the enzyme. At present, there are about a thousand types of resistance-related β -lactamases [5,9-13]. This give a rough picture of the diversity that bacteria possess to fight against the drugs we currently use. Intense and regular usage of antibiotics in hospitals have led to nosocomial (hospitalacquired) infections which has turned into a global health challenge. One such infectious agent is *Staphylococcus aureus* (*S. aureus*) which has developed resistance rapidly to many antibiotics. By 1944, just four years after the introduction of penicillin, *S. aureus* strains resistant to penicillin had emerged and were prevalent by 1950s [14]. So far, *S. aureus* has developed resistance to Erythromycin, chlortetracycline and chloramphenicol, methicillin (MRSA), vancomycin (VRSA) and daptomycin [15-18]. Streptomycin was initially used to treat Tuberculosis; however, multi-drug resistant *Mycobacterium tuberculosis* strain in the current days ranges from XDR (Extremely drug-resistant) strains to TDR (totally drug resistant) strains [19]. Bacteria has been shown to acquire resistance to antibiotics is a very short time period; *Escherichia coli* was shown to gain resistance to ciprofloxacin in a matter of 10 hours [20] Novel metabolites such as Gepotidacin [21], cathelicidin [22], Rhodethrin [23], Rubrivivaxin [24], etc were discovered in the recent past showing promising antimicrobial activity. However, as discussed previously, resistance to any antibiotic is only a matter of time. Hence, there isa nurgent need to tackle the current multidrug resistant pathogens. Vaccines are of biological origin which provides acquired immunity to the body. It relies on body's ability to remember how to defend itself against foreign agents from a previous attack by the same pathogen. Application of vaccines can directly reduce the need of antibiotics against the pathogen and indirectly against other

Mini Review

Volume 4 Issue 1 - 2017

Madangchanok Imchen and Ranjith Kumavath*

Central University of Kerala, India

*Corresponding author: Ranjith Kumavath, Department of Genomic Science, School of Biological Sciences, Central University of Kerala, Padanakkad P.O., Kerala-671314, Kasaragod, India, Tel: +91-8547648620; Email: rnkumavath@gmail.com

Received: February 12, 2017 | Published: February 22, 2017

pathogens by avoiding super-infections [25]. The ability of vaccines to provide herd immunity has eradicated polio and other deadly diseases such as measles [26]. Unlike antibiotics, there have been no reports on bacterial resistance to vaccines. Vaccines also does not exert massive selective pressure on the environment [27]. However, those serotypes not covered by the vaccines could spread at a higher rate such as the seven-valent pneumococcal conjugate vaccine (PCV7) against *Streptococcus pneumonia* [28-30]. The advent of the omics field has given rise to vaccinomics [31,32] which is based on high throughput Next Generation Sequencing (NGS) and robust bioinformatics pipelines technologies. Such technologies aims to solve the problem related to hyper variable virus and to developed personalized based vaccines. In addition, the human gut micro biome project [33] could lead to other therapeutic options [34]. The advent of new technology could help to reduce the cost of vaccines. Hence, the possibility to combat against the disease previously failed and affordable to the undeveloped countries with the aim to eradicate deadly Vaccine-preventable diseases (VBDs) [35-38].

References

1. Demain AL, Sanchez S (2009) Microbial drug discovery: 80 years of progress. *J Antibiot* (Tokyo) 62(1): 5-16.
2. Miller GHM, Pant P, Gandra SS, Levinson J, Barter D, et al. (2015) The state of the world's antibiotics. *Wound Healing Southern Africa* 8(2): 30-34.
3. Hanif A, Ashar SM, Rabnawaz R, Yasmeen S (2016) Self medication of Antibiotics among the Students of Hamdard University, Pakistan. *Journal of Public Health in Developing Countries* 2(1): 145-148.
4. Mainous AG, Everett CJ, Post RE, Diaz VA, Hueston WJ (2009) Availability of antibiotics for purchase without a prescription on the internet. *Ann Fam Med* 7(5): 431-435.

5. Davies J, Davies D (2010) Origins and evolution of antibiotic resistance. *Microbiol Mol Biol Rev* 74(3): 417-433.
6. Laxminarayan R, Duse A, Wattal C, Zaidi AK, Wertheim HF, Sumpradit N et al. (2013) Antibiotic resistance-the need for global solutions. *The Lancet Infect Dis* 13(12): 1057-1098.
7. Arias CA, Murray BE (2009) Antibiotic-resistant bugs in the 21st century-a clinical super-challenge. *N Engl J Med* 360(5): 439-443.
8. Nikaido H (2009) Multidrug resistance in bacteria. *Annu Rev Biochem* 78: 119-146.
9. Bush K, Jacoby G A (2010) Updated functional classification of β -lactamases. *Antimicrob Agents Chemother* 54(3): 969-976.
10. Jacoby GA (2009) AmpC β -lactamases. *Clinical microbiology reviews* 22(1): 161-182.
11. Livermore DM, Canton R, Gniadkowski M, Nordmann P, Rossolini GM, et al. (2007) CTX-M: changing the face of ESBLs in Europe. *J Antimicrob Chemother* 59(2): 165-174.
12. Poirel L, Naas T, Nordmann P (2010) Diversity, epidemiology, and genetics of class D β -lactamases. *Antimicrob Agents Chemother* 54(1): 24-38.
13. Queenan AM, Bush K (2007) Carbapenemases: the versatile β -lactamases. *Clinical microbiology reviews* 20(3): 440-458.
14. DeLeo FR, Chambers HF (2009) Reemergence of antibiotic-resistant *Staphylococcus aureus* in the genomics era. *J Clin Invest* 119(9): 2464-2474.
15. Finland M (1979) Emergence of antibiotic resistance in hospitals, 1935-1975. *Rev Infect Dis* 1(1): 4-22.
16. Grundmann H, Aires de Sousa M, Boyce J, Tiemersma E (2006) Emergence and resurgence of methicillin resistant *Staphylococcus aureus* as a public health threat. *Lancet* 368(9538): 874-885.
17. Cameron DR, Howden BP, Peleg AY (2011) The interface between antibiotic resistance and virulence in *Staphylococcus aureus* and its impact upon clinical outcomes. *Clin Infect Dis* 53(6): 576-582.
18. Vilhena C, Bettencourt A (2012) Daptomycin: a review of properties, clinical use, drug delivery and resistance. *Mini reviews in Mini Rev Med Chem* 12(3): 202-209.
19. Velayati AA, Masjedi MR, Farnia P, Tabarsi P, Ghanavi J, et al. (2009) Emergence of new forms of totally drug-resistant tuberculosis bacilli: super extensively drug-resistant tuberculosis or totally drug-resistant strains in Iran. *Chest* 136(2): 420-425.
20. Zhang Q, Lambert G, Liao D, Kim H, Robin K, et al. (2011) Acceleration of emergence of bacterial antibiotic resistance in connected microenvironments. *Science* 333(6050): 1764-1767.
21. Biedenbach DJ, Bouchillon SK, Hackel M, Miller LA, Scangarella Oman NE, et al. (2016) *In vitro* activity of gepotidacin, a novel triazaacenaphthylene bacterial topoisomerase inhibitor, against a broad spectrum of bacterial pathogens. *Antimicrob Agents Chemother* 60(3): 1918-1923.
22. Gao W, Xing L, Qu P, Tan T, Yang N, et al. (2015) Identification of a novel cathelicidin antimicrobial peptide from ducks and determination of its functional activity and antibacterial mechanism. *Sci Rep* 5: 17260.
23. Ranjith NK, Sasikala CH, Ramana CHV (2007) Rhodethrin: a novel indole terpenoid ether produced by *Rhodobactersphaeroides* has cytotoxic and phytohormonal activities. *Biotechnol Lett* 29(9): 1399-1402.
24. Kumavath RN, Raman CHV, Sasikala CH (2011) Rubrivivaxin, a new cytotoxic and cyclooxygenase-I inhibitory metabolite from *Rubrivivaxbenzoatilyticus* JA2. *World Journal of Microbiology and Biotechnology* 27(1): 11-16.
25. Kwong JC, Maaten S, Upshur RE, Patrick D M, Marra F (2009) The effect of universal influenza immunization on antibiotic prescriptions: an ecological study. *Clin Infect Dis* 49(5): 750-756.
26. Rappuoli R, Mandl CW, Black S, De Gregorio E (2011) Vaccines for the twenty-first century society. *Nat Rev Immunol* 11(12): 865-872.
27. Mishra RP, Oviedo Orta E, Prachi P, Rappuoli R, Bagnoli F (2012) Vaccines and antibiotic resistance. *Curr Opin Microbiol* 15(5): 596-602.
28. Hicks LA, Harrison LH, Flannery B, Hadler JL, Schaffner W, et al. (2007) Incidence of pneumococcal disease due to non-pneumococcal conjugate vaccine (PCV7) serotypes in the United States during the era of widespread PCV7 vaccination, 1998-2004. *J Infect Dis* 196(9):1346-1354.
29. Weinberger DM, Malley R, Lipsitch M (2011) Serotype replacement in disease after pneumococcal vaccination. *Lancet* 378(9807): 1962-1973.
30. Feikin DR, Kagucia EW, Loo JD, Link Gelles R, Puhan MA, et al. (2013) Serotype-specific changes in invasive pneumococcal disease after pneumococcal conjugate vaccine introduction: a pooled analysis of multiple surveillance sites. *PLoS Med* 10(9): e1001517.
31. Poland GA, Ovsyannikova IG, Jacobson RM (2008) Personalized vaccines: the emerging field of vaccinomics. *Expert Opin Biol Ther* 8(11): 1659-1667.
32. Sette A, Rappuoli R (2010) Reverse vaccinology: developing vaccines in the era of genomics. *Immunity* 33(4): 530-541.
33. Turnbaugh PJ, Ley RE, Hamady M, Fraser Liggett CM, Knight R, et al. (2007) The human microbiome project: exploring the microbial part of ourselves in a changing world. *Nature* 449(7164): 804-810
34. Qin J, Li R, Raes J, Arumugam M, Burgdorf KS, et al. (2010) A human gut microbial gene catalogue established by metagenomic sequencing. *Nature* 464(7285): 59-65.
35. Abdelmohsen UR, Balasubramanian S, Oelschlaeger TA, Grkovic T, Pham NB (2016) Potential of marine natural products against drug-resistant fungal, viral, and parasitic infections. *Lancet Infect Dis* 17(20): e30-e41.
36. Fleming A (1950) *Penicillin: Its Practical Application*. Academic Medicine 25(4): 1-303.
37. Guinovart MC, Figueras A, Llor C (2016) Selling antimicrobials without prescription - Far beyond an administrative problem. *Enferm Infect Microbiol Clin*: S0213-005X(16)30321-S0213-005X(16)30324.
38. Simmons HE, Stolley PD (1974) This is medical progress?: trends and consequences of antibiotic use in the United States. *JAMA* 227(9): 1023-1028.